Fragment-based drug discovery requires higher throughput to process large numbers of fragments within a short amount of time and high sensitivity to reliably detect the weak affinity interactions of low molecular weight analytes. The Pall ForteBio Pioneer FE system lets you screen for identification of fragment candidates on large numbers of sample and obtain reliable affinity (KD) and kinetic (ka, kd) data directly from the primary screens.
This webinar will provide an overview of the Pioneer platform technology and its application in a real-life discovery workflow.
Dr. Aman Singh will present the results of a 5000 fragment screening and hit triaging effort to find alternative ClpP binders using the Pioneer FE system. Caseinolytic Protease P (ClpP) represents an important emerging target for the treatment of chronic bacterial infections. Acyldepsipeptides (ADEPs) specifically target the ClpP allosteric activation domain resulting in deregulated hyper-activation of ClpP, leading to self-digestion of pathogenic bacteria. A retrospective analysis of success of Surface Plasmon Resonance (SPR), Thermal Shift Assay (TSA), and Fluorescence Polarization (FP) assays against this complex protein-protein interaction site target will also be presented.